Gilbertsville, PA. April 9, 2013 – Rockland Immunochemicals, Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, assay development, and preclinical studies, today announced the acquisition of the Epi-Plus® antibody product line from 21st Century Biochemicals, Inc.
Epi-Plus® antibodies are widely regarded as the most well validated antibodies available for epigenetics research. All Epi-Plus® antibodies are multi-assay validated, including dot blot testing using modified peptide arrays, western blots, and chromatin immunoprecipitation (ChIP).
Current research in Epigenetics, the study of changes in gene expression or cellular phenotype, has shown that epigenetic pharmaceuticals could be a putative replacement or adjuvant therapy for currently accepted treatment methods such as radiation and chemotherapy. The global revenue market for epigenetics has been estimated at $2.6 Billion in 2012 and is expected to reach $8 Billion by 2017, a five-year CAGR of 25%.
"The acquisition of the Epi-Plus® product line expands Rockland’s Life Science Tools portfolio and will allow our customers to perform their research in a more efficient and effective manner, ultimately saving time and precious research dollars," commented Jim Fendrick, President and CEO of Rockland Immunochemicals. “The fact that the Epi-Plus® brand is co-owned by Novus Biologicals also allows us to expand the Rockland brand globally."
“As 21st Century Biochemicals continues to focus its efforts on providing US manufactured custom peptide and antibody solutions for its customers, we are pleased that the Epi-Plus® product line is a strong strategic fit for the Rockland portfolio,” added Dr. Jordan Fishman, President and CSO of 21st Century Biochemicals.
Rockland will market the Epi-Plus® product line on its e-commerce website and through its existing global distribution network. Detailed product information can be found at http://www.rockland-inc.com/epigenetic_antibodies.aspx.
About Rockland Immunochemicals
Rockland Immunochemicals has supported the academic, biopharma and diagnostic industries with antibodies and antibody based tools™ for over 50 years. At its U.S. based facilities, Rockland produces and distributes research reagents ideally suited for integration into various assays performed on different platforms including western blot (WB), immunohistochemistry (IHC), immunofluorescence microscopy (IF), ELISA and FLOW cytometry. Additional information about Rockland’s products and services can be found on the company’s web site at www.rockland-inc.com.
For additional information regarding this announcement, please contact:
Communications, Rockland Immunochemicals, Inc.